Patent · US Active

Compounds for treatment of cystic fibrosis

US10130622B2 · kind B2 · utility

0Cited by

0References

33Claims

0Family size

Assignees

AbbVie S.á.r.l. · LU
Galapagos NV · BE

Inventors

Rhalid Akkari · Pantin, FR
Luke Jonathan Alvey · Versailles, FR
Xavier Marie Bock · Romainville, FR
Brian S. Brown · Evanston, US
Pieter Isabelle Roger Claes · Gentbrugge, BE
Marlon D. Cowart · Round Lake Beach, US
Katja Conrath · Mechelen, BE
Douglas Cyr · Chapel Hill, US
Elsa De Lemos · Paris, FR
Gert Jules Hector De Wilde · Mechelen, BE
Nicolas Desroy · Romainville, FR
Béranger Duthion · Romainville, FR
Gregory A. Gfesser · Lindenhurst, US
Romain Luc Marie Gosmini · Savigny-sur-Orge, FR
Christopher Gaëtan Housseman · Montreuil, FR
Koen Karel Jansen · Turnhout, BE
Jianguo Ji · Libertyville, US
Philip R. Kym · Libertyville, US
Jean-Michel Lefrancois · Livry-Gargan, FR
Oscar Mammoliti · Mechelen, BE
Christel Jeanne Marie Menet · Mechelen, BE
Nuria Merayo Merayo · Paris, FR
Gregory John Robert Newsome · Neuilly-Plaisance, FR
Adeline Marie Elise Palisse · Brussels, BE
Sachin V. Patel · Round Lake, US
Mathieu Rafaël Pizzonero · Voisins-le-Bretonneux, FR
Anurupa Shrestha · Vernon Hills, US
Elizabeth C. Swift · Highland Park, US
Chris Tse · Libertyville, US
Steven Emiel Van der Plas · Mechelen, BE

Key dates

Filing date	Oct 7, 2016
Grant date	Nov 20, 2018
Priority date	—
Expiry date	Oct 7, 2036

Classification

Technology area (CPC G)Physics
CPC primaryG01N2800/382
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

A corrector agent capable of stabilizing a newly synthesized cystic fibrosis transmembrane conductance regulator (CFTR) protein, useful in the treatment of cystic fibrosis.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.